Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP Young semaglutide weight management study in children and adolescents
2022-502922-41-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in BMI. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2022-502922-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502922-41-00.